Clinical Trial Update: Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of oral vorinostat in combination with topotecan for chemosensitive recurrent small cell lung cancer, which…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Topotecan (topotecan)
• Vorinostat (vorinostat)

Snippet

Sponsor: Armando Santoro, MD | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED